RENE GONZALEZ to Humans
This is a "connection" page, showing publications RENE GONZALEZ has written about Humans.
Connection Strength
0.453
-
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704.
Score: 0.013
-
Anti-CTLA4 antibody therapy related complications on FDG PET/CT. Clin Nucl Med. 2014 Jan; 39(1):e93-6.
Score: 0.012
-
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236.
Score: 0.011
-
Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors. Semin Oncol. 2012 Apr; 39(2):139-44.
Score: 0.011
-
Novel therapies in melanoma. Immunotherapy. 2011 Dec; 3(12):1461-9.
Score: 0.010
-
Immunologic therapy targeting metastatic melanoma: allovectin-7. Immunotherapy. 2011 Jan; 3(1):17-21.
Score: 0.010
-
A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010 Jun; 20(3):218-26.
Score: 0.009
-
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010 Jan 01; 116(1):155-63.
Score: 0.009
-
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6.
Score: 0.009
-
Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature. Int J Dermatol. 2009 Apr; 48(4):426-30.
Score: 0.009
-
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs. 2008 Feb; 26(1):89-94.
Score: 0.008
-
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007 Oct; 14(10):2854-60.
Score: 0.008
-
Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res. 2006 Dec; 16(6):521-6.
Score: 0.007
-
Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol. 2006 Aug 01; 94(2):101-4.
Score: 0.007
-
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
Score: 0.007
-
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan; 24(1):89-94.
Score: 0.007
-
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest. 2005; 23(4):303-8.
Score: 0.006
-
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. Int J Cancer. 2024 Nov 15; 155(10):1792-1807.
Score: 0.006
-
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15; 130(10):1784-1796.
Score: 0.006
-
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
Score: 0.006
-
Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma. Expert Opin Biol Ther. 2003 Apr; 3(2):377-84.
Score: 0.006
-
A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma. Invest New Drugs. 2002 Aug; 20(3):357-62.
Score: 0.005
-
A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer. 2002 Jan 15; 94(2):470-6.
Score: 0.005
-
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
Score: 0.005
-
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022 01 10; 40(2):127-137.
Score: 0.005
-
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Res. 2021 02 01; 31(1):67-75.
Score: 0.005
-
Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. Mol Cancer Res. 2021 02; 19(2):346-357.
Score: 0.005
-
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020 10 16; 11(1):5259.
Score: 0.005
-
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). J Clin Oncol. 2020 09 01; 38(25):2916-2925.
Score: 0.005
-
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 04; 85(4):673-683.
Score: 0.005
-
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
Score: 0.005
-
A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. J Surg Oncol. 2019 Dec; 120(7):1276-1283.
Score: 0.004
-
Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
Score: 0.004
-
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 10 17; 381(16):1535-1546.
Score: 0.004
-
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019 06; 25(6):929-935.
Score: 0.004
-
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019 04 10; 37(11):867-875.
Score: 0.004
-
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019 02 18; 7(1):49.
Score: 0.004
-
68Ga-DOTA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging. Sci Transl Med. 2018 11 07; 10(466).
Score: 0.004
-
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1480-1492.
Score: 0.004
-
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018 Oct; 63:282-291.
Score: 0.004
-
Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. J Neurooncol. 2018 Oct; 140(1):55-62.
Score: 0.004
-
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res. 2017 12; 27(6):585-590.
Score: 0.004
-
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45.
Score: 0.004
-
ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther. 2018 01; 17(1):222-231.
Score: 0.004
-
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 2018 03 01; 36(7):667-673.
Score: 0.004
-
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 10 05; 377(14):1345-1356.
Score: 0.004
-
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017 11 09; 377(19):1824-1835.
Score: 0.004
-
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017 Dec 01; 35(34):3807-3814.
Score: 0.004
-
Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017 09; 82:80-91.
Score: 0.004
-
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544.
Score: 0.004
-
NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 08; 14(8):945-58.
Score: 0.004
-
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Apr; 14(4):450-73.
Score: 0.004
-
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun. 2016 Feb; 37(2):122-8.
Score: 0.003
-
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8.
Score: 0.003
-
Association of sentinel lymph node diameter with melanoma metastasis. Am J Surg. 2016 Aug; 212(2):315-20.
Score: 0.003
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
Score: 0.003
-
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Jul 02; 373(1):23-34.
Score: 0.003
-
Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015 May; 72(5):780-5.e3.
Score: 0.003
-
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
Score: 0.003
-
Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015 Jan 01; 21(1):175-83.
Score: 0.003
-
A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma. Cancer Med. 2015 May; 4(5):643-50.
Score: 0.003
-
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
Score: 0.003
-
A review of novel therapies for melanoma. Am J Clin Dermatol. 2014 Aug; 15(4):323-37.
Score: 0.003
-
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
Score: 0.003
-
Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014 May; 12(5):621-9.
Score: 0.003
-
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24.
Score: 0.003
-
High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):197-202.
Score: 0.003
-
New targeted therapies in melanoma. Cancer Control. 2013 Oct; 20(4):282-8.
Score: 0.003
-
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
Score: 0.003
-
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
Score: 0.003
-
Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013 May; 148(5):456-61.
Score: 0.003
-
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74.
Score: 0.003
-
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9.
Score: 0.003
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 11 01; 367(18):1694-703.
Score: 0.003
-
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9.
Score: 0.003
-
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy. 2012 Jul; 4(7):679-86.
Score: 0.003
-
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-2450.
Score: 0.003
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23; 366(8):707-14.
Score: 0.003
-
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15.
Score: 0.003
-
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15; 17(24):7765-75.
Score: 0.003
-
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 02; 364(22):2119-27.
Score: 0.003
-
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34.
Score: 0.002
-
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011 Oct 15; 117(20):4732-9.
Score: 0.002
-
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug 01; 116(15):3683-91.
Score: 0.002
-
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 363(8):711-23.
Score: 0.002
-
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010 Apr 15; 16(8):2402-8.
Score: 0.002
-
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
Score: 0.002
-
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol. 2009 Dec 20; 27(36):6207-12.
Score: 0.002
-
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01; 27(34):5763-71.
Score: 0.002
-
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009 Nov 10; 27(32):5452-8.
Score: 0.002
-
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30.
Score: 0.002
-
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
Score: 0.002
-
The absent-minded professor: an unusual complication of melanoma. Oncology (Williston Park). 2008 Dec; 22(14):1609-14.
Score: 0.002
-
PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs. 2008 Nov; 17(11):1769-76.
Score: 0.002
-
Increased survival from stage IV melanoma associated with fewer regulatory T Cells. J Surg Res. 2009 Jun 01; 154(1):13-20.
Score: 0.002
-
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85.
Score: 0.002
-
A case of Merkel cell carcinoma. Oncology (Williston Park). 2008 Mar; 22(3):322-8.
Score: 0.002
-
Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer. 2007 Jan 17; 7:13.
Score: 0.002
-
Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 2006 Dec; 192(6):878-81.
Score: 0.002
-
Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass. Oncology (Williston Park). 2006 Jun; 20(7):763-70.
Score: 0.002
-
Lymphangiomatosis masquerading as metastatic melanoma. Am Surg. 2006 Apr; 72(4):367-70.
Score: 0.002
-
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res. 2006 Feb 15; 12(4):1137-43.
Score: 0.002
-
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005 Nov 01; 23(31):8057-64.
Score: 0.002
-
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol. 2005 Dec 10; 23(35):8992-9000.
Score: 0.002
-
Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg. 2005 Jun; 40(6):988-92; discussion 992.
Score: 0.002
-
Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg. 2005 Jan; 140(1):85-9.
Score: 0.002
-
Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg. 2005 Jan; 40(1):232-5.
Score: 0.002
-
A young woman with melanoma diagnosed during pregnancy. Oncology (Williston Park). 2004 Jun; 18(7):794-9.
Score: 0.002
-
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
Score: 0.001